Study Shows Varied Results from Different Methods of Measuring Albumin
|
By LabMedica International staff writers Posted on 21 Feb 2017 |

Image: A structural model of serum albumin (Photo courtesy of Wikimedia Commons).
A recent paper compared the accuracy of several different methods for determining levels of serum or plasma albumin, measurements, which are used to evaluate the nutritional status, kidney function, and fluid balance of dialysis patients.
Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.
Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.
“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”
The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.
The study was published in the January 2017 issue of the journal Clinical Chemistry.
Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.
Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.
“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”
The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.
The study was published in the January 2017 issue of the journal Clinical Chemistry.
Latest Clinical Chem. News
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
Channels
Molecular Diagnostics
view channel
Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing
Fluoropyrimidines such as 5-fluorouracil (5-FU) are chemotherapy drugs prescribed to more than two million cancer patients each year, but 10–20% of patients can experience severe, and sometimes fatal,... Read more
Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer
High-risk non–muscle-invasive bladder cancer frequently recurs after therapy, with about 30% of patients relapsing and roughly 10% dying within two years despite tumor resection, surveillance, and Bacillus... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read more
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
AI Tool Automates Validation of Laboratory Software Configuration Changes
Regulated laboratories face heavy documentation and requalification demands when software configurations change, slowing improvements and discouraging beneficial updates. A new capability now automates... Read more
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read moreIndustry
view channel
Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
Selecting treatments for advanced cancer remains difficult when bulk analyses mask the functional diversity of tumor cells and mechanisms of resistance that emerge over time. Clinicians increasingly need... Read more








